Regenerative Medicine Claims: A Reader’s Guide to Evidence, Uncertainty, and Questions

Most regenerative medicine claims — for stem cells, platelet-rich plasma (PRP), exosomes, or “biologics” — are not FDA-approved for the condition being advertised. The U.S. Food and Drug Administration (FDA) has approved only one category of stem cell product for general use: blood-forming stem cells from umbilical cord blood, for disorders that affect blood production.

Everything else marketed for pain, orthopedic injuries, neurological disease, autism, or anti-aging is either unapproved, still being tested in a registered clinical trial, or sold with no research oversight at all. Knowing which of those three categories a specific claim falls into is the most useful skill for evaluating regenerative medicine marketing, and it’s the organizing idea behind this guide. If you’re new to how we cover evidence topics on this site, Start Here is a good place to begin.

Why is regenerative medicine marketing so confusing to evaluate?

Regenerative medicine marketing borrows the language of real science — “clinical study,” “FDA-registered,” “biologic,” “next-generation” — without always meaning what those words mean in a regulatory sense. A clinic can be legally registered as a business and still offer a product that has never been reviewed by the FDA for safety or effectiveness. A study can exist and still be too small, too short, or too poorly controlled to support a treatment claim.

This guide does not tell you whether any specific procedure is right for you. It gives you a way to sort claims by their evidence level so you can ask sharper questions before you spend money or agree to a procedure. Our How We Research page explains the sourcing standard behind guides like this one.

What’s the difference between a claim, a study, and FDA approval?

Before evaluating any specific claim, it helps to separate four things that marketing language frequently blurs together.

• A claim is a statement made in advertising, on a clinic website, or by a provider — for example, “our stem cell therapy repairs cartilage.” A claim is not evidence; it’s the thing that needs evidence behind it.
• A study is a specific piece of research with a design, a sample size, and a result. Studies vary enormously in quality — a small case series of 12 patients with no comparison group is a very different kind of evidence than a large randomized controlled trial.
• Regulatory status is whether the FDA has approved the specific product for the specific use being marketed, whether it’s being studied under an active Investigational New Drug (IND) application, or whether it has no FDA oversight at all.
• An unanswered question is something researchers themselves say they don’t yet know, such as how long a benefit lasts or which patients are most likely to respond.

A trustworthy source will usually let you tell these four things apart. A red flag is when they’re deliberately blended — for example, when a clinic implies that being “registered with a clinical trial database” means “FDA-approved,” which it does not.

How strong is the evidence? An evidence ladder for regenerative medicine claims

Use this ladder to place any specific claim you encounter. Higher rungs mean stronger, more independently verified evidence. Lower rungs mean the claim is resting on less, even when the marketing language sounds confident.

1. Rung 1 — FDA-approved for this specific use. The product has gone through the FDA’s formal review process and is approved for the exact condition being marketed. This currently applies to a narrow category: certain blood-forming stem cell products derived from cord blood, for specific blood-related disorders. Almost nothing else marketed as “stem cell therapy” meets this bar.
2. Rung 2 — Being studied under an active FDA Investigational New Drug (IND) application. A formal research plan is registered with the FDA, and the product is being tested under federal oversight, typically inside a clinical trial with defined safety monitoring. This is real research, but it is not the same as proven or approved.
3. Rung 3 — Published clinical research outside FDA oversight. A study may exist in a medical journal without the product ever having gone through FDA review for that use. The strength of this rung depends entirely on study design: randomized controlled trials with adequate sample sizes and long-term follow-up sit higher than small, uncontrolled case series or single-clinic outcome reports.
4. Rung 4 — No registered trial, no FDA oversight, marketing claims only. This is the category most consumers actually encounter when a clinic advertises a proprietary or “exclusive” regenerative treatment. At this rung, the claim rests on the clinic’s own description of its own results, not on independently verified evidence.

A simple decision path follows from this ladder: if a provider cannot tell you which rung their product sits on, or cannot produce documentation for that rung, treat that gap itself as information. It means the claim has not yet been made verifiable to you. The FDA is explicit that being charged for a regenerative medicine product outside of a legitimate clinical trial, without FDA approval, is a warning sign — not a neutral fact about how healthcare is normally delivered.

What does the evidence currently establish, and what’s still unknown?

This section separates what research organizations state with confidence from what they say remains unresolved. It is not a summary of any single product — it reflects the general state of the field as described by the FDA and the National Institutes of Health (NIH).

What is established

• FDA approval for stem cell products is currently limited to specific cord-blood-derived products for blood-related disorders.
• Products marketed for pain, orthopedic conditions, neurological disease, autism, vision loss, or COVID-19-related symptoms are not FDA-approved for those uses.
• Regulators have documented real safety events connected to unapproved regenerative products, including infections, tumors, vision loss, and unwanted immune reactions, tied in part to contamination and inconsistent product quality.
• A product being “registered” in a public clinical trial database is not the same as being approved or proven effective.

What remains unresolved

• How long any benefit from a given regenerative procedure typically lasts.
• Which patients, if any, are most likely to respond to a given approach.
• Whether cells delivered through many marketed procedures behave the way marketing materials describe once inside the body — the NIH notes that requirements like proper cell survival, integration, and long-term function remain unmet for most proposed applications outside approved uses.
• How outcomes from small, single-clinic case series would hold up in larger, independently run trials.

What questions should I ask before evaluating any specific claim?

These questions are drawn directly from FDA and NIH consumer guidance. They’re designed to help you find out where a claim sits on the evidence ladder above, not to tell you what decision to make.

• Is this exact product FDA-approved for this exact condition, or is that being implied rather than stated directly?
• If it’s not approved, is it being studied under an active FDA Investigational New Drug application, and can the provider show you that documentation?
• Is the supporting study a randomized controlled trial, or a smaller case series without a comparison group?
• Who funded or conducted the research being cited — an independent institution, or the clinic and product seller themselves?
• What does the provider say about what is not yet known, not just what the treatment claims to do?
• Where would a suspected side effect or adverse event from this product be reported?

What should I do if something goes wrong after a regenerative medicine procedure?

The FDA maintains a formal channel for regenerative medicine safety concerns. If you or someone you know experiences a suspected side effect or complication connected to a stem cell, PRP, exosome, or other regenerative product, the FDA directs consumers to report it through the MedWatch Adverse Event Reporting program, or to contact the FDA’s Office of Combination Products directly. A medical emergency should always be directed to local emergency services first, before any reporting step.

What’s a practical next-step checklist before a consultation?

Use this checklist to organize your own research before a consultation or appointment. It is a way to prepare informed questions, not medical guidance, and it does not tell you what to decide.

1. Write down the exact product name and the exact condition it’s being marketed for.
2. Check current FDA and NIH resources for the approval status of that category of product.
3. Ask the provider directly whether the product is FDA-approved for your specific condition, being offered under an active IND application, or neither.
4. Ask what independent, non-clinic-funded research exists, and what study design that research used.
5. Ask what the provider says is still unknown about long-term outcomes.
6. Note where you would report a side effect, before any procedure, not after.

Frequently asked questions about regenerative medicine claims

Does a clinic being registered as a business mean its regenerative medicine product is legitimate?

No. Business registration and FDA product approval are two separate things. A clinic can be a legally operating business while offering a product that has never been reviewed by the FDA for safety or effectiveness in the condition it’s marketed for.

Does a listing on a public clinical trial database mean a treatment is FDA-approved or proven effective?

No. A product being registered in a clinical trial database means research is underway, not that the FDA has approved it or that it has been proven to work. The FDA specifically warns that this distinction is often blurred in marketing.

What products are typically marketed as “regenerative medicine” outside FDA approval?

Products commonly marketed under this label include stem cells, fat-derived cells, cord blood products, amniotic fluid products, exosomes, and other ortho-biologics. According to the FDA, nearly all of these fall outside current FDA approval when marketed for conditions like pain, orthopedic injuries, or neurological disease.

What safety problems have been reported with unapproved regenerative medicine products?

Regulators have documented adverse events including infections, tumors, vision loss, and unwanted immune responses, with some cases linked to contamination during product processing. These are documented regulatory findings, not a prediction of what will happen with any specific product.

Where do I report a bad reaction to a stem cell or regenerative medicine product?

The FDA’s MedWatch Adverse Event Reporting program is the designated channel for this, alongside direct contact with the FDA’s Office of Combination Products. A medical emergency should go to local emergency services first, before filing any report.

What this guide is not

This article is educational information only. It does not diagnose any condition, recommend for or against any treatment, or tell you to start, stop, or change any medical care. Regenerative Evidence Guide is an independent educational publication and is not affiliated with, and does not represent, any clinic, faculty, training program, or conference formerly associated with this domain.

We do not provide medical credentials, continuing education, or clinical services. For guidance specific to your health, consult a licensed healthcare provider. Read our medical information disclaimer for more detail on the limits of this content.

Sources: U.S. Food and Drug Administration, “Important Patient and Consumer Information About Regenerative Medicine Therapies” (fda.gov); National Institutes of Health, “Stem Cell Basics” (stemcells.nih.gov).

By Regenerative Evidence Guide Editorial Team

Updated September 7, 2026